Latest Safety News

Etherstack plc has reported its highest ever half-year cash receipts, surpassing US$7 million in the first half of FY2025, signaling strong momentum and a promising revenue outlook for the year.

Catalyst Metals has received the final environmental approval to begin mining at its Trident Gold Project, marking a key step in its plan to double production at the Plutonic Gold Belt.

Chimeric Therapeutics reports encouraging interim results from its ADVENT-AML Phase 1B trial, with two of three newly diagnosed AML patients achieving remission using their novel CORE-NK cell therapy combined with standard treatment.

Paradigm Biopharmaceuticals has secured centralised US ethics approval for its pivotal Phase 3 trial of injectable pentosan polysulfate sodium (iPPS) targeting moderate to severe knee osteoarthritis, setting the stage for patient enrolment in Q3 2025.

Amplia Therapeutics reports a significant milestone in its ACCENT trial, with 15 confirmed partial responses indicating that narmafotinib combined with chemotherapy outperforms chemotherapy alone in advanced pancreatic cancer.

Immutep’s novel immunotherapy combination with KEYTRUDA and chemotherapy shows a 60.8% response rate in first-line non-small cell lung cancer, outperforming historical benchmarks especially in patients with low PD-L1 expression.

Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.

Alliance Aviation Services has updated its FY25 financial guidance, aiming for EBITDA between $205-210 million while navigating operational disruptions and planning significant debt reduction by 2026.

Carbine Resources has been granted a long-term mining lease for its Muchea Silica Sand Project, marking a significant step forward while awaiting further regulatory approvals.

Austco Healthcare has landed a $2.1 million deal to supply its Tacera nurse call system for a major new patient and surgical tower at Toronto Western Hospital, marking a significant step in its North American expansion.

Anteris Technologies has submitted its FDA Investigational Device Exemption for the pivotal PARADIGM Trial of its DurAVR heart valve and marked a milestone of 100 patients treated, while expanding manufacturing capacity amid rising R&D costs.

Life360, Inc. reported a strong Q1 2025 with 32% revenue growth to $103.6 million, driven by a 33% increase in subscription revenue and a return to profitability with $4.4 million net income. The company also advanced its strategic positioning through a $4.5 million acquisition and a key partnership.